Renal Dysfunction and Liver Transplantation by Naglaa Allam
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
13 
Renal Dysfunction and Liver Transplantation 
Naglaa Allam 
National Liver Institute, Menoufeyia University,  
Egypt 
1. Introduction 
Liver transplantation, whether living donor (LDLT) or deceased donor (DDLT), is currently 
the treatment of choice for patients with advanced liver disease. While initially the focus 
was on acceptable short-term survival, currently the efforts are aimed at improving long-
term prognosis. Thus, focus is now on the quality of life after liver transplantation, as well as 
prediction and management of conditions related to morbidity and mortality in long-term 
survivors. Renal dysfunction is an important problem in this scenario. Both acute (ARD) and 
chronic renal dysfunctions (CRD) develop frequently after liver transplantation and can 
seriously jeopardize postoperative patient survival.  
Acute kidney injury is one of the most common complications of liver transplantation. It 
occurs more frequently in those who have hepatorenal syndrome at the time of liver 
transplantation. Acute renal dysfunction has been associated with an 8-fold increase in 
mortality risk, prolonged intensive care unit stay and a greater risk for infectious 
complications. In the subgroup of patients who develop acute renal failure and survive, 80% 
to 90% regain some degree of renal function, whereas the rest develop permanent renal 
dysfunction. Chronic renal dysfunction, not only has implications in terms of an increased 
demand on resources, but is also significantly associated with a higher patient mortality 
rate. 
In order to minimize the occurrence of ARD and CRD thereafter, it is vital to define the 
possible preoperative, intraoperative and postoperative risk factors. In this review, we 
discuss the various definitions, diagnostic tools, predictors of renal dysfunction after liver 
transplantation together with discussion of specific causes of renal dysfunction. This 
information will be useful in developing strategies for preventing the development or 
progression of renal dysfunction in liver transplant recipients, especially in view of the 
current availability of nonnephrotoxic immunosuppressive drugs. 
2. Assessment of renal function prior to transplantation 
With broadening of the inclusion criteria for liver transplantation, the majority of liver 
transplant recipients have some impairment of renal function prior to transplantation and 
most have clinically apparent renal insufficiency at some time in the posttransplant period. 
Among those with renal impairment at the time of transplant are patients whose renal 
failure is due to the same underlying process that caused the liver disease (hepatitis B, 
hepatitis C, analgesic overdose, amyloidosis, autoimmune disease), patients with underlying 
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parenchymal renal disease from diseases such as diabetes and hypertension, and other 
patients in whom the functional renal impairment is caused by the liver failure itself and its 
complications. The latter group may have manifestations ranging from mild sodium 
retention to oliguric renal failure termed hepatorenal syndrome (HRS) (Smith, 2006). 
For both prognostic and therapeutic reasons it is important to assess the level of renal function 
in patients being considered for liver transplantation and to determine if there is any 
reversible component. Also given organ shortage it should be essential to determine which 
patients will experience progressive and severe renal dysfunction after liver transplantation 
(Burra et al., 2009). 
2.1 Methods of measurement of renal function 
The most commonly used markers of glomerular filtration rate (GFR), blood urea nitrogen 
(BUN) and serum creatinine (Scr), have limitations that should be kept in mind, especially in 
the setting of liver transplantation. Because urea is generated by the liver from the 
metabolism of protein and ammonia, both malnutrition and poor hepatic function may 
cause a falsely low BUN that can lead to an overestimation of GFR. Conversely, 
corticosteroids, bleeding (particularly in the gastrointestinal tract), and renal hypoperfusion 
cause higher BUN levels than one would expect for a given level of GFR (Cholongitas et al., 
2007 a).  
Also current diagnostic paradigms for acute kidney injury are limited by reliance on serum 
creatinine (Scr), which is affected by age, gender, nutrition and the amount of muscle mass 
which may render the values inaccurate. Thus, most patients with endstage liver disease 
with decreased muscle mass may have a misleadingly low Scr. In addition, elevations in Scr 
may occur several days after the actual injury (Fieghen et al., 2009). Also, a number of 
medications (including trimethoprim) inhibit the secretion of creatinine, so that when these 
medications are used, Scr may rise without any true change in GFR (Cholongitas et al., 
2007). Furthermore, creatinine is both filtered and secreted by the nephron, so that its 
clearance is an overestimate of GFR. It should also be noted that the relationship between 
the serum creatinine and GFR is not linear; at high levels of GFR, the Scr is insensitive to 
large changes in GFR, while at low levels of GFR, small changes in GFR cause large changes 
in serum creatinine (Mariat et al., 2004). A problem, not often recognized is that 
measurement of Scr suffers from a variety of interferences (Cholongitas et al., 2007 b) and 
absence of international standard for measurement (Seronie-Vivien et al., 2005). Serum 
creatinine is usually measured by the Jaffè method, but this is prone to interference, for 
example, from protein, ketones and bilirubin. Hence, hyperbilirubinemia often impacts on 
the measurement of Scr in endstage liver disease population (Owen et al., 2006). These 
findings can result in an underestimation of renal function.  
Despite the above limitations, the endogenous creatinine clearance from a timed urine 
collection or as calculated from the Cockcroft–Gault formula {(140- age)/Cr × (weight in 
kg/72) (× 0.85 for females)} (Cockcroft and Gault, 1976) remains the most common measure 
of GFR (Lewandowska  & Matuszkiewicz-Rowinska, 2011). If a timed urine collection is 
performed, the amount of creatinine excreted in 24 hours should be 12–25 mg/kg body 
weight as a crude test for completeness of the collection. Because of the variability in the 
accuracy of timed collections performed by outpatients, and the excellent correlation of the 
Cockcroft–Gault calculation with timed creatinine clearance measurements under controlled 
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conditions, a timed collection may be necessary only for a baseline creatinine clearance and 
to measure protein excretion. It can then be repeated only as necessary to confirm abrupt or 
unexpected changes in the serum creatinine (Smith, 2006). However, it should be noted that 
there is some debate concerning the use of the Cockcroft–Gault equation to estimate GFR 
(Gonwa et al., 2004). This formula may be inaccurate and pick up small differences in GFR 
that are statistically significant but clinically irrelevant. Although GFR calculations often 
overestimate GFR measurements (Poge et al., 2005), even using the best formulas available, 
the Cockcroft–Gault equation has been used in many published studies and was widely 
used in clinical practice (Burra et al., 2009). 
Modification of diet in renal disease (MDRD) equation (Levey et al., 1999) is another method 
that is considered more accurate than other formulas to measure GFR in patients with intact 
kidney function. MDRD equation: GFR = 170 x [Serum creatinine]-0.999 x [Age]-0.176 x 
[0.762 if patient is female] x [1.180 if patient is black] x [BUN]-0.170 x [Albumin] + 0.318. 
Most often, the formula, excluding urea and albumin (four variables), is used to calculate 
GFR, as it is as accurate as the original six-variable formula (Levey et al., 2006). Neither these 
formulas nor calculation of creatinine clearance from a 24-hour urine collection has been 
well studied or validated in patients with decompensated cirrhosis. Preliminary data 
suggest that the MDRD equation is more precise in liver transplant (LT) patients than other 
renal formulas, but the MDRD equation actually underestimates GFR measured by the gold 
standard of iothalamate clearance. There are now online calculators that provide a 
convenient way to estimate GFR (e.g. http://nephron.com/gi-bin/MDRDSIdefault.cgi) 
(Fabrizi et al., 2010). However, in LT recipients, even the best performing equation, the six-
variable MDRD equation, provides an estimate that is within 30% of the actual GFR only 
two-thirds of the time (Gonwa et al., 2004). 
Ideally, renal function can be estimated through the use of inulin, (125I) iothalamate, or 
51Cr-EDTA clearance methods, but these are costly and often impractical. Many nuclear 
medicine departments perform isotopic GFR measurements based on the decay of the 
plasma level of an injected radiolabeled GFR marker over a few hours (Mariat et al., 2004). 
However the cost of the radiolabeled GFR markers and the precautions needed in handling 
them make these tests expensive. 
2.2 Diagnosis of pre-transplant kidney dysfunction 
Patients with cirrhosis are candidates to develop acute renal failure from different causes; 
each of them requiring specific treatments. In cirrhotic patients with ascites, pre-renal failure 
(42%) and acute tubular necrosis (ATN) (38%) represent the most common forms of acute 
renal failure while hepatorenal syndrome (HRS) is somewhat less frequent (20%) (Fasolato 
et al., 2007). Approximately 18% will develop HRS at 1 year and 39% at 5 years (Terra et al., 
2005). However, it may be difficult to identify the cause and start the appropriate treatment 
(Moreau and Lebrec, 2003). The different causes of acute renal failure in cirrhotics are 
discussed below. Table 1 shows the differential diagnosis of the causes that are most 
commonly encountered during preparation for liver transplant. 
2.2.1 Hepatorenal syndrome  
Patients with end-stage liver disease may exhibit a spectrum of functional renal impairment 
from mild sodium retention and clinically inapparent reduction in GFR, to an oliguric state 
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with severe intrarenal vasoconstriction, avid sodium conservation, and very low GFR 
referred to as hepatorenal syndrome (Eckardt, 1999). In almost half the cases of HRS, one or 
more precipitating factors may be identified, including bacterial infections (57%), 
gastrointestinal hemorrhage (36%), and large volume paracentesis (7%) (Fasolato et al., 
2007). The hallmark of HRS is intense renal vasoconstriction with predominant peripheral 
arterial vasodilation. Kidney histology is normal (Wadei et al., 2006). 
HRS is a diagnosis of exclusion, requiring the absence of sepsis and nephrotoxic agents, less 
than 500 mg/day of protein excretion and no microhaematuria, an ultrasound showing no 
evidence of obstruction or parenchymal renal disease, and a lack of improvement of serum 
creatinine (<1.5mg/dl) with cessation of diuretic therapy and plasma volume expansion 
(albumin 1 g/kg upto max. of 100g/day) (New International Ascites Club’s diagnostic criteria of 
hepatorenal syndrome (Salerno et al., 2007). If the syndrome persists, acute tubular necrosis 
may result. Thus, the urine sodium concentration is less than 10 meq/L early in the process, 
but as tubular ischemia occurs, the urine sodium rises, clouding the diagnostic issue. 
2.2.2 Volume depletion induced renal dysfunction 
Prerenal failure usually occurs in patients with decompensated cirrhosis. These patients 
already have significant circulatory dysfunction characterized by low arterial pressure, renal 
vasoconstriction and decreased renal blood flow; but they have no or only mild reduction in 
GFR. Volume depletion further decreases renal blood flow and induces a marked decline in 
GFR which may be rapidly reversible if the underlying cause is corrected (Moreau and 
Lebrec, 2003). Ten to twenty percent of patients with gastrointestinal hemorrhage have 
hypovolemic shock on admission. This true hypovolemia is one cause of prerenal azotemia. 
A retrospective study showed that 5% of patients with cirrhosis hospitalised for acute upper 
gastrointestinal hemorrhage had early renal failure that lasted less than 7 days after index 
bleeding (Cardenas et al., 2001). Patients admitted for hemorrhage may also develop 
prerenal failure due to other causes such as bacterial infection (Cardenas et al, 2001).  
True hypovolemia and subsequent renal failure may also result from vomiting, diarrhea, 
glycosuria or diuretic treatment used to mobilize ascites. 
2.2.3 Severe sepsis  
Patients with cirrhosis are susceptible to bacterial infections, in particular spontaneous 
bacterial peritonitis (SBP). Septic shock and subsequent prerenal azotemia occurs in 10% of 
patients with SBP. At the onset of SBP, 20-40% of patients have renal failure without shock 
(Moreau and Lebrec, 2006). Thirty percent of those admitted for SBP or for another bacterial 
infection develop type 1 HRS during hospitalization (Terra et al., 2005). 
2.2.4 Drugs 
NSAIDS 
Cyclo-Oxygenase (COX)-derived vasodilator prostaglandins protect renal perfusion in 
patients with cirrhosis and ascites. Hence administration of non-selective non-steroidal anti-
inflammatory drugs (NSAIDs) (i.e., drugs that can inhibit cyclooxygenase-1 (COX-1)) and 
cyclooxygenase-2) in cirrhotic patients may lead to marked renal hypoperfusion and 
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subsequent prerenal failure following COX inhibition induced by non-selective NSAIDs. It 
was also shown that COX-2 inhibitors, like non-selective NSAIDs, may also induce prerenal 
failure in patients with cirrhosis and ascites (FitzGerald and Patrono, 2001). 
Antibiotics 
Patients with cirrhosis and ascites are predisposed to aminoglycoside nephrotoxicity, the 
reported incidence of which (32%) is much higher than that found by other investigators in 
the general population (3–11%). Aminoglycoside nephrotoxicity is associated with a marked 
deterioration in renal function (Cabrera et al., 1982). Patients with decompensated cirrhosis 
are prone to develop this complication, since they frequently have impaired renal blood 
flow and glomerular filtration rates, and renal accumulation of aminoglycosides is greater 
with renal impairment (Moore et al., 1984). 
2.2.5 Contrast induced nephropathy 
This is defined as impairment of renal function subsequent to the administration of contrast 
media in the absence of any other cause. Contrast induced nephropathy (CIN) is diagnosed 
when there is an increase in serum creatinine concentration of > 0.5 mg/dl or a relative 
increase of > 25% from the baseline within 72 hrs after contrast media administration 
(Barrett and Parfrey, 1994).  
Pre-existing renal dysfunction and diabetes mellitus are the two most important risk factors 
for CIN. The incidence of CIN is less than 2% when basal creatinine is less than 1.6 mg/dl 
and increases to 12-29% when above 1.6 mg/dl and to 38% when above 2.0 mg/dl. The 
presence of more than one risk factor increases the risk to develop CIN by many folds (Liu 
et al., 2005). The incidence of CIN also rises with increase in the volume of the contrast 
media. It is less than 2% when patients receive less than 125 ml of contrast media compared 
with 19% in patients receiving more than that volume. Peri-procedural hydration is 
regarded as a simple and effective means to prevent CIN. Results of a large number of 
clinical trials go in favour of post-procedural acetylcystine which is a free radical scavenger 
and precursor of antioxidant glutathione (Tepel et al., 2006). Recovery occurs in the majority 
of cases within 2–3 weeks; few patients require dialysis for recovery (Barrett & Parfrey, 
1994). 
2.2.6 Intrinsic renal failure 
2.2.6.1 Viral hepatitis and associated glomerular diseases 
Viral infections such as hepatitis B (HBV) and C (HCV) are well-known to induce 
concomitant severe hepatic and renal injuries with ultimate endstage renal disease. The 
most common clinical presentation in both cases is the nephrotic syndrome with a slowly 
progressive decline in renal function (Lai & Lai, 1991 and Johnson et al., 1994a). The 
proteinuria remits spontaneously in a minority of patients, but may also recur. The degree 
of proteinuria appears to correlate with viremia as spontaneous remission of the 
glomerulopathy is usually associated with clearance of viral antigens from the blood. The 
mechanisms whereby different viral infections induce distinct glomerular lesions and/or 
systemic complications have not been fully elucidated. Circulating and most likely in situ 
immune complexes involving viral antigens and host anti-viral antibodies have been 
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implicated in hepatitis B- associated membranous glomerulonephropathy (Pham et al., 
2005).  
HCV-related glomerulonephritis 
Hepatitis C has been associated most closely with mesangiocapillary glomerulonephritis 
(Bursten & Rodby, 1993, Johnson et al., 1993 & Johnson et al., 1994b). Many of the patients with 
chronic HCV and mesangiocapillary glomerulonephritis also have hypocomplementemia, 
cryoglobulinemia (the cryoprecipitates contain HCV-RNA), and rheumatoid factors (IgM 
antibodies directed against anti-HCV antibodies). Other symptoms and signs of mixed 
cryoglobulinemia such as skin lesions, arthritis, and neuropathy may not be present. Indeed, 
even the hepatitis associated with the renal disease may be asymptomatic and the 
transaminases may be normal (Johnson et al., 1994b). Less commonly, non-cryoglobulinemic 
mesangiocapillary glomerulonephritis, focal and segmental glomerulosclerosis, mesangial 
proliferation with IgA deposition, fibrillary and immunoactoid glomerulopathies occur (Dore 
et al., 2007). A purely membranous glomerulonephritis has also been reported in patients with 
HCV, and may have a different pathogenesis (Stehman-Breen et al., 1995). McGuire et al 
performed kidney biopsies at the time of liver transplantation in 30 patients with HCV-related 
cirrhosis and a median creatinine of 1.4 mg/dL; immune complex glomerulonephritis was 
reported in 83% of the patients (McGuire et al., 2006). 
   
A. Increased cellularity, expansion of mesangium,  
Thickening & splitting of capillary walls 
   B. Capillary wall deposits of Ig G 
   
C. Capillary wall deposits of IgM D. EM of glomerular capillary: subendothelial 
immune deposits as tactoids (arrows) & 
microtubules (arrowheads) characteristic of 
cryoglobuinns 
Fig. 1. Renal Biopsy specimen from a patient with Hepatitis C (Johnson et al., 1993) 
www.intechopen.com
 
Renal Dysfunction and Liver Transplantation 
 
279 
HBV-related glomerulonephritis 
HBV-related glomerulonephritis is more often found in children. Membranous 
glomerulonephritis is the most common form of HBV-related glomerulonephritis, but 
mesangiocapillary glomerulonephritis, mesangial proliferative glomerulonephritis, focal 
segmental glomerulosclerosis, IgA nephropathy and minimal change disease have all been 
described. In addition, in patients with HBV-associated polyarteritis nodosa, a variety of 
histologic patterns have been documented (Lai & Lai, 1991). Immune complexes of hepatitis 
B surface, core, and e antigens as well as antibodies together with complement components 
have been demonstrated in glomerular basement membrane and mesangium. HBV antigens 
have been localized in the glomeruli using immunofluorescent antibodies, electron 
microscopy, and molecular techniques. HBeAg has been consistently associated with 
capillary basement membrane deposits (membranous form of glomerulopathy), while 
HBsAg is more closely associated with deposits in the mesangium (Lai and Lai., 1991; 
Takekoshi et al., 1991). 
Liver disease tends to be mild in patients who present with HBV-related 
glomerulonephritis. Disease remission is especially evident after HBeAg seroconversion. A 
significant percent of adults (30%) may progress to renal failure and as many as 10% will 
require maintenance dialysis (Bhimma et al., 2002).  
2.2.6.2 Renal disease associated with poor hepatic function 
Patients with poor hepatic function of any cause may develop parenchymal renal disease 
manifested by nonnephrotic proteinuria, microscopic hematuria, and reduced GFR. The 
most common histologic picture is a mesangiopathic glomerulonephritis with deposition of 
IgM and often IgA, perhaps because of impaired clearance by the liver. It has not been 
proved that these immune complexes are the cause of the renal disease (Smith, 2006). 
 Prerenal  
Azotemia 
Acute tubular 
Necrosis 
Hepatorenal  
Syndrome 
Primary 
Nephropathy 
 Urine sodium <10 mEq/L  >30 mmol/L <10 mmol/L >30 mmol/L 
Urine to plasma  
creatinine ratio 
>30:1 <20:1 >30:1 <20:1 
Proteinuria <100mg <500mg <500mg Variable 
Table 1. Differential Diagnosis of Acute renal failure in advanced liver disease. (Eckardt, 1999) 
Renal failure post liver transplantation 
Renal insufficiency, whether acute renal failure (ARF) or chronic kidney disease (CKD), is a 
common complication after liver transplantation and represents a major cause of morbidity 
and mortality following LT (Yalavarthy et al., 2007). 
3. Acute renal failure 
3.1 Epidemiology 
Acute renal failure (ARF) is one of the most common complications of liver transplantation 
(LT), with a variable incidence rate in different studies. The incidence of acute kidney injury 
(AKI) has been reported to vary between 17% to 95% post-liver transplantation (Bilbao et al., 
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1998, Lima et al., 2003). The difference in the incidence reported may be due in part to the 
large difference in the criteria used to define ARF. 
Campbell et al., 2005 and Lebrón Gallardo et al., 2004 used a value of serum creatinine 
above 1.5 mg/dl as diagnostic of acute Kidney injury (AKI) and reported an incidence as 
high as 64%. On the other hand, Junge et al, 2006, reported a relatively low incidence of 
11.9% and defined AKI post-LT as serum creatinine of 2.5 mg/dl in the first week only. 
Actually the incidence rate of post-LT ARD differs even in the same center when variable 
definitions are used. Barri and colleagues, 2009 conducted a study on 1050 patients who 
underwent LT, using changes in serum creatinine from baseline as the main marker for 
acute kidney injury (AKI). They used three different definitions to diagnose post-LT AKI. 
Defining AKI as a rise in serum creatinine of >0.5 mg/dL resulted in the highest incidence 
of AKI (78%). The second definition of AKI was a rise in serum creatinine of >1 mg/dl and 
this resulted in an incidence of AKI 46%. When AKI was defined as a rise of serum 
creatinine of >50% from baseline to above 2 mg/dl, the lowest incidence of AKI (14%) was 
found (Barri et al., 2009). Hence, these variations in definitions cause difficulties in 
comparing different studies and demonstrate the need for a consensus in the diagnosis of 
acute renal disease after LT. 
3.2 Definition of acute renal failure 
Several researchers have evaluated the problem of renal impairment post-LT but it is 
difficult to meaningfully compare these studies as a series of different definitions are used 
(Cabezuelo et al., 2002).  
To address this issue, RIFLE classification was introduced in 2002. RIFLE is an acronym for 
risk of renal dysfunction, injury to the kidney (ARI), failure of the kidney (ARF), loss of 
kidney function and end-stage kidney disease (Table 2). It was later modified and is 
functioning as AKIN (Acute Kidney Injury Network) classification since 2005 (Table 3). The 
AKI term includes a wide range of renal dysfunction, starting with a very early and discrete 
renal failure with minimal changes in the serum creatinine level (stage 1, Risk), through 
moderate changes (stage 2, Injury), to an advanced renal failure (stage 3, Failure), often 
requiring renal replacement therapy (Bellomo et al., 2004 & Mehta et al., 2007). Two 
additional stages (Loss of function and Endstage- renal-disease) were introduced in order to 
classify cases of a partial or total and permanent loss of renal function. Some studies used 
these criteria to determine the incidence of ARF post-LT. Kundakci reported that AKD 
occurred in more than half of LTs postoperatively. AKI occurred in 64 (57%) LTs with risk, 
injury, and failure frequencies of 19%, 11%, and 28%, respectively (Kundakci et al., 2010). 
Zhu et al reported that postoperatively, AKI was found in 60% of patients. According to the 
AKIN criteria, it was: stage 1 – in 30%, stage 2 – in 13%, and stage 3 – in 17% of the 
individuals (Zhu et al., 2010). 
AKIN classification was introduced with great enthusiasm, but soon proved to be of little 
use. Its main disadvantages include undersensitivity and no reference to aetiology or 
pathophysiology of AKI. Thus, it does not distinguish between the prerenal azotemia and a 
real injury of the renal parenchyma. Serum creatinine level and eGFR based on it are not 
useful parameters in the early diagnostics of AKI. First of all, the increase in creatinine level 
occurs late, after a few days, with an injury of more than 50% of the renal parenchyma. 
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Moreover, it is influenced by too many factors of creatinine synthesis and secretion in the 
renal tubules. In patients with graft dysfunction, these indicators are even less reliable, 
because of malnutrition and – frequently observed in these patients – high levels of serum 
bilirubin which interferes with creatinine measurements and causes a significant reduction 
in serum creatinine level (Cholongitas et al., 2007a). 
Risk Increase of serum creatinine  
1.5-2 times baseline 
Less than 0.5ml/kg/hr for 
>6hrs 
Injury Increase of serum creatinine  
2-3 times baseline 
Less < 0.5ml/kg/hr for >12hrs 
Failure Increase of serum creatinine of  
> 3 times baseline 
<0. <0.3ml/kg/hr for >24hrs or 
anuria>12hrs
Loss Persistent need for RRT 
for >4 weeks 
End-stage Persistent need for RRT  
for >3 months 
 
Table 2. Risk, Injury, Failure, Loss of Kidney Function, End-stage (RIFLE) Kidney Disease 
classification (Mehta et al., 2007) 
Acute Kidney Injury Recovery 
Stage1 Stage 2 Stage 3 
Loss of function>4 weeks 
but <3 months 
Rise in serum  
creatinine ≥0.3 mg/dl or 
Increase to ≥150%  
to 200%  
(1.5-fold to 2-fold)  
from baseline. 
Increase in serum 
creatinine to  
> 200%- 300%  
(> 2-fold to 3-fold)  
from baseline. 
Increase in serum 
creatinine to > 300% 
(> 3-fold) from baseline, 
or serum creatinine  
≥4.0 mg/dl with an 
acute increase of  
at least 0.5 mg/dl. 
End-stage renal failure 
>3 months 
Urine output < 0.5 
ml/kg/hour for > 6 hrs.
Urine output < 0.5 
ml/kg/hour for > 12 
hrs. 
Urine output < 0.3 
ml/kg/hr for 24 hrs, or 
anuria for 12 hrs. 
Death 
Table 3. Classification/staging system for acute kidney injury modified from RIFLE criteria. 
(Bellomo et al., 2004) 
3.3 Aetiology and risk factors of acute kidney injury after liver transplantation 
In order to apply protective strategies to minimize the occurrence of acute renal dysfunction 
(ARD) and chronic renal dysfunction thereafter, it is vital to define risk factors for ARD and 
manage properly as early as possible (Barri et al., 2009). 
The evaluation of predictive factors for renal failure that occurs postoperatively has been the 
matter of several investigations. Clinical studies evaluating these risk factors have yielded 
variable results. Although the risk factors for AKI are often multifactorial and difficult to 
establish, they can be linked to three distinct time frames in relation to the liver transplant: 
the pretransplant (pre-LT), intraoperative, and post-LT periods as follows: pre-transplant 
(HRS, pre-transplant kidney dysfunction, high bilirubin concentrations), intra-operative 
www.intechopen.com
 
Liver Transplantation – Technical Issues and Complications 
 
282 
(hemodynamic instability, intraoperative bleeding), and postoperative factors (contrast 
nephropathy, acute tubular necrosis secondary to ischemic or toxic agents, liver allograft 
dysfunction, multiple antibiotic use, reoperations especially re-transplantation). Actually the 
most common cause of ARF early after LTx is ischemic acute tubular necrosis, followed later 
by cyclosporine toxicity and sepsis (Fabrizi et al., 2010). 
Preoperative Intraoperative Postoperative 
Pretransplant renal 
dysfunction 
Hepatorenal syndrome 
High MELD score 
Preexisting Diabetes 
mellitus 
Hypertension 
Hyponatremia 
Hemodynamic instability 
during anesthesia 
Longer anhepatic phase 
Intraoperative bleeding 
Volume of transfused 
blood products 
Intraoperative acidosis 
Hypovolemia 
Need for pressor amines 
Haemodynamic instability 
Perioperative volume of 
transfused blood products. 
Sepsis. 
Relaparotomy. 
Contrast nephropathy 
Delayed liver graft function or 
primary graft nonfunction 
Calcineurin inhibitors 
Drug-induced interstitial 
nephritis. 
HCV recurrence 
Table 4. Risk factors for Post liver transplant Acute Renal Dysfunction  (Lewandowska & 
Matuszkiewicz-Rowinska, 2011) 
3.3.1 Pretransplant renal dysfunction 
The rate of renal failure among patients awaiting liver transplantation (LT) and the waiting 
time for LT have increased in recent years. The introduction of the Model for End-Stage 
Liver Disease (MELD) score will likely further enrich the proportion of LT candidates who 
have renal dysfunction, as creatinine is a key component of MELD calculation. The decision 
to perform combined kidney/liver transplantation (CKLT) as opposed to liver 
transplantation alone can be difficult in patients with end-stage liver disease and recent 
onset renal insufficiency. Because of scarce organ resources, it is important to predict 
accurately which patients with pretransplant renal dysfunction will recover after LT and 
who will have persistent or progressive kidney disease. 
*Pretransplantation serum creatinine level: is an important predictor of post-LT survival and 
renal dysfunction (Brown et al., 1996, Lafayette et al.,1997,  Bilbao et al., 1998, Markmann et 
al., 2001, Nair et al., 2002, Pawarode et al., 2003 and Campbell et al., 2005). Even relatively 
mild elevations in preoperative creatinine (>1.0-1.5 mg/dL) may portend poor renal function  
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postoperatively (Lafayette et al., 1997, Bilbao et al., 1998 and  Pawarode et al., 2003). Bilbao 
(1998), Sanchez (2004) and Yalavarthy (2007) observed that preoperative creatinine >1.5 
mg/dl was predictive of the need for postoperative renal replacement therapy (RRT) and 
also the risk of postoperative infection. Contreras et al reported that preoperative blood urea 
nitrogen was also an important predictive factor for the need for renal replacement therapy 
post-transplant (Contreras et al., 2002). Nair et al, (2002) demonstrated that patients with an 
average preoperative serum creatinine of 0.8 mg/dl had a 5-year patient survival of 62% 
compared to a 5-year survival of only 42% in patients with a preoperative serum creatinine 
of 2.7 mg/dL. Organ Procurement and Transplantation Network/United Network for 
Organ Sharing (OPTN/UNOS) data from 1988 to 1995 demonstrated that patients with a 
preoperative serum creatinine >2 mg/dl had a 5-year survival of only 50%. Furthermore, 
patients requiring preoperative RRT had worse outcomes compared to those not requiring 
RRT (Jeyarajah et al., 1997).  
Cause of renal disease 
May also help predict posttransplantation creatinine. Certainly patients with underlying 
chronic kidney diseases such as glomerulonephritis, diabetic nephropathy would be expected to 
have persistently poor or worsening renal function after LT alone, particularly in the setting 
of calcineurin inhibitor–based immunosuppression. Sezer et al., reported that 
microalbuminuria is a main risk for renal function deterioration (Sezer et al., 2011). Many 
transplant centers have reported that a large majority of their CKLT patients underwent 
transplantation for chronic kidney disease. In contrast, hepatorenal syndrome (in studies 
from the early 1990s) demonstrated a good post-LT alone renal outcome and hence 
concomitant renal transplantation may be avoided. Of patients with ARF due to the 
hepatorenal syndrome, approximately two-thirds will recover, although recovery may be 
delayed 3 months or longer after LT (Yalavarthy et al., 2007). Because waiting times for liver 
transplantation and duration of renal dysfunction prior to transplantation have increased 
since then, it is possible that renal outcomes after LT alone in patients with HRS may be less 
favorable now. 
Duration of pretransplant renal dysfunction 
Bahirwani et al., 2008 showed that patients with preexisting renal dysfunction, especially if 
the duration is more than 12 weeks, experience a significant fall in eGFR after liver 
transplantation alone.  
Most studies agreed on reporting the negative impact of pretransplant renal dysfunction on 
posttransplant renal function, regardless of the criteria that they depended upon to define 
the dysfunction. Lebrón Gallardo (2004), Faenza (2006) and Burra (2009), used serum creatinine; 
Gonwa et al., 2004 used pre-LT GFR & Kim et al., 2004 used creatinine clearance. Indeed 
mortality after LT is affected modestly by the presence of pretransplant acute renal failure 
(<2-fold increase), but increases markedly (up to 8-fold) in the face of acute renal failure 
posttransplant (Yalavarthy et al., 2007). 
3.3.2 MELD score 
The proportion of patients undergoing liver transplantation (LT) with renal insufficiency 
has significantly increased after the MELD era due to the fact that more patients with high 
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serum creatinine are being transplanted and hence affecting the posttransplant kidney 
function (Sharma et al., 2009). An association was observed between postoperative ARF and 
a higher Model for End-Stage Liver Disease (MELD) score (Sanchez et al., 2004, Campbell et 
al., 2005, Tinti et al., 2010 and Sezer et al., 2011) and between ARF and a reduced pre-LT 
serum albumin (Tinti et al., 2010). No association was noted between ARF and other pre-LT 
parameters. The association of ARF with MELD and hypoalbuminemia may be the result of 
a close relationship between renal and hepatic functions among cirrhotic patients (Tinti et 
al., 2010). Schnitzbauer reported that time on the waiting list with endstage hepatic disease 
is a major risk factor associated with early posttransplant renal impairment (Schnitzbauer et 
al., 2010). 
3.3.3 Early liver allograft dysfunction 
Several studies reported that early liver allograft dysfunction is among the major risk factors 
associated with early posttransplant renal impairment (Fraley et al.,1998, Gainza et al., 2002, 
Ojo et al., 2003, Lebrón Gallardo et al., 2004, Cabezuolo et al., 2006, Yalavarthy et al., 2007 
and Schnitzbauer et al., 2010). Small-for-size (SFS) grafts, which may lead to specific problems 
of delayed function or SFS syndrome (characterized by prolonged cholestasis, ascites or 
coagulopathy) may also aggravate the problem of post-transplant renal dysfunction. Lee et 
al., 2007 in their study on 248 adult patients who underwent LDLT reported a significant 
relationship between small-for-size grafts (GRWR < 0.8) and early postoperative renal 
dysfunction. Yamamoto et al., 2004 also demonstrated this relationship. 
3.3.4 CNI nephrotxicity 
Acute, reversible nephrotoxicity accompanying CNI therapy results from the imbalance in 
vasoactive substance release. The administration of CNI causes vasoconstriction of both the 
afferent and, to a greater degree, the efferent arterioles, which leads to a decrease in renal 
blood flow and glomerular filtration rate (GFR), and an increase in renal vascular resistance. 
In its most extreme form, there is tubular damage and a clinical picture of acute tubular 
necrosis, perhaps on the basis of ischemia. Kidney biopsy histopathology shows 
characteristic isometric vacuoles in proximal and distal tubular cells. Calcineurin inhibitors 
can also cause an acute form of nephrotoxicity manifested by acute renal failure in the early 
posttransplant period. Renal biopsy in these patients shows endothelial damage, formation 
of fibrin thrombi in capillary loops (Fig. 2), eosinophilic material in the walls of arterioles 
and small arteries, with patchy necrosis of smooth muscle cells. This lesion is histologically 
similar to that seen in malignant hypertension and thrombotic thrombocytopenic purpura. 
Indeed, thrombocytopenia sometimes accompanies this syndrome in transplanted patients 
(Remuzzi & Bertani, 1989).  
Diagnosis of ARF 
Vigilant postoperative care including not only monitoring of renal parameters, but also a 
thorough analysis of risk factors of renal dysfunction is vital. 
3.4 Postoperative monitoring of renal parameters 
At present, monitoring of the renal function bases mostly on the results of the serum 
creatinine level and the estimated glomerular filtration rate (eGFR rate) calculated with the 
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use of MDRD and Cockcroft-Gault formula and on monitoring of diuresis (Cockcroft & 
Gault, 1976 and Levey et al., 1999).  
 
Fig. 2. Thrombotic angiopathy of cyclosporine toxicity. The arrowheads point to fibrin 
thrombi in the capillary loops of a glomerulus from a patient with acute cyclosporine 
toxicity. (Smith, 2006: Photomicrograph courtesy of David Howell)  
Because of the above-mentioned limitations of AKIN criteria, it is now attempted to find 
new biomarkers released by the renal tubules, which (if increased in urine or blood serum) 
would allow for an early diagnosis of AKI or identification of a group at increased risk of 
AKI. The most frequently mentioned indicators of this type include: cystatin C (Biancofiore 
et al., 2006), NGAL (neutrophil gelatinase-associated lipocalin) (Portal et al., 2010), KIM-1 (kidney 
injury molecule-1) or interleukin-18 (Lewandowska  & Matuszkiewicz-Rowinska, 2011). 
Recently, there have been a few reports published that evaluated the usefulness of the latest 
methods of an early AKI assessment in post-LT patients. Portal et al. evaluated the 
usefulness of serum and urine NGAL level measurements in patients immediately after liver 
transplantation, in prognosing the risk of AKI development within the next 48 hours. A 
multivariate regression analysis showed two independent risk factors of AKI development: 
APACHE II (OR 1.64/point; 95% CI, 1.22–2.21, P=0.001) and serum NGAL level (OR 
1.01/ng/ml, 95% CI, 1.00–1.02, P=0.002). When combined together (so called renal risk 
index), these two factors revealed the highest predictive value. Index with APACHE II score 
of >13 and serum NGAL level of >258 ng/ml, calculated at ≥1, showed a sensitivity of 100% 
and a specificity of 76% in the prediction of severe AKI [Portal et al., 2010]. 
3.4.1 Analysis of risk factors 
Xu and colleagues, on the basis of the analysis of data from 102 patients subjected to LT, 
developed a predictive model of AKI incidence following LT. A multivariate analysis 
showed that independent risk factors of this complication included: preoperative creatinine 
level of >1.2 mg/dl, intraoperative diuresis of ≤60 ml/hour, intraoperative hypotension,  
and use of noradrenaline. They calculated the risk score as follows: [–2.128 + 1.109× 
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(preoperative creatinine level of >1.2 mg/dl) + 2.243 × (intraoperative diuresis of ≤60 ml/hr) 
+ 1.542 × (intraoperative hypotension) – 2.463 × (intraoperative use of noradrenaline)]. Next, 
the authors studied the usefulness and predictive value of the developed formula in a 
prospective study including 44 patients after LT, assuming that the probability of AKI = 
EXP (risk score)/ [1 + EXP (risk score)]. Aiming to achieve the highest sensitivity and 
specificity of the indicator (75% and 93.8%, respectively), a cut-off value of –0.2 was 
assumed as optimal in determining the prognosis of AKI. This meant that among patients 
with an index value of ≥–0.2, the risk of AKI development was significantly higher than in 
patients with an index value of <–0.2. The model developed by the authors proved to be 
reliable: AKI occurred in 9 out of 11 patients from the group of high risk, and only in 3 
individuals out of 33 from the low-risk group (Xu et al., 2010). 
3.5 Prevention of acute renal dysfunction 
To prevent acute kidney injury effectively, it is necessary to know its risk factors, to evaluate 
the patient in detail before liver transplantation, and to obey the rules of conduct, 
characteristic for all clinical situations that could lead to AKI development. 
3.5.1 General measures 
- thorough monitoring of the water and electrolyte balance,  
- avoidance of nephrotoxic drugs,  
- discontinuation of preparations inhibiting the effect of angiotensin II,  
- careful dosing of other medicines, with adjustments of doses to the current renal 
function. 
Unfortunately, despite promising results of in vitro and experimental studies, it was 
impossible to prove the protective effect of N-acetylcysteine on kidneys in that population 
(Hilmi et al., 2010, Sagias et al., 2010 and Jegatheeswaran & Siriwardena, 2011).  
3.5.2 Modification of nephrotoxic immunosuppressive regimens  
To avoid postoperative acute renal failure and/or chronic renal failure has met with 
variable results (Fabrizi et al., 2010). There are no data to suggest that switching from one 
calcineurin inhibitor to another at equipotent doses will result in less nephrotoxicity. 
However, as trough tacrolimus levels correlate more closely with the area under the curve of 
drug exposure than do trough cyclosporine levels, it may be easier to avoid calcineurin 
inhibitor toxicity using tacrolimus. If cyclosporine is used, the blood level drawn 2hrs post 
dose (C2 level) should be used to monitor therapy. 
Strategies to limit CNI exposure include CNI minimization, avoidance, and withdrawal 
Candidates for such a treatment would be first of all patients with impaired renal function 
found before transplantation. There is no well-defined protocol to prevent or minimize 
cyclosporine or tacrolimus nephrotoxicity.  
Some centers advocate Calcineurin inhibitor minimization using mycophenolate mofetil or 
sirolimus. This may be associated with a modest increase in creatinine clearance (CrCl) and 
a decrease in serum creatinine (SCr) in the short term. Mycophenolate mofetil may improve 
renal outcomes during CNI minimization more than sirolimus. Despite improvement in  
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CrCl or SCr, CNI nephrotoxicity is progressive over time when CNI exposure is maintained. 
Persistent damage is observed on biopsies as long as the CNIs are continued.  
CNI withdrawal 
May be the best option by delivering CNIs during the early period of immunologic graft 
injury and then converting them to less nephrotoxic agents before significant renal damage 
occurs (Flechner et al., 2008). Late CNI withdrawal has achieved variable results, possibly 
because withdrawal was attempted after the kidney damage was too extensive. In a case 
report on 3 patients with renal function impairment who switched from CNI to sirolimus, 2 
improved substantially and came off dialysis, while in 1 (whose renal dysfunction was 
initially milder, not severe enough to require dialysis) serum creatinine levels remained 
altered after switching to sirolimus (Kamar et al., 2007). Early CNI withdrawal, prior to 
significant kidney damage, has generally improved CrCl and markers of fibrosis, a finding 
also observed with sirolimus in most studies. Successful withdrawal appears to be more 
effective than CNI minimization. Lam et al stressed that sirolimus conversion should be 
initiated early since late conversion rarely improves chronic renal dysfunction (Lam et al., 
2004). In fact, several studies have shown that in patients with pre-existing renal disease, 
sirolimus can even worsen nephrotoxicity and promote proteinuria (Bumbea et al., 2005, 
Letavarnier et al., 2005 and Diekmann et al., 2007). 
Antibody induction with delayed CNI initiation 
It has been suggested that in case of high serum creatinine levels at the time of grafting, it 
may be wise to delay the use of calcineurin inhibitor based immunosuppression in the 
immediate post-operative period (Distant & Gonwa, 1993). Polyclonal antibody 
(thymoglobulin) induction was used to delay CNI use and avoid renal toxicity without 
increasing the risk of rejection or HCV recurrence. However side-effects such as “first dose 
reaction” have been reported in 80% of patients. This can often be ameliorated by 
premedication with antipyretics and steroids. Other side-effects include thrombocytopenia, 
CMV infection, posttransplant lymphoproliferative disease (PTLD), serum sickness and 
anaphylaxis (Pillai & Levitsky, 2009).  
Later, monoclonal antibody induction using basiliximab (anti-CD25 monoclonal anti-body) 
and alemtuzumab (anti-CD 52 antibody) was used. These antibodies remain in the 
circulatory system for weeks after initiation of therapy and have been used successfully with 
low-dose CNIs. Neuhaus (2002) and Liu (2004) reported successful use of basiliximab with 
less nephrotoxicity and fewer side-effects compared to the antithymocyte globulins. Also, 
Tzakis (2004) and Marcos (2004) showed that liver transplant recipients who received 
alemtuzumab induction with low dose tacrolimus had less renal toxicity than those who 
received standard doses of tacrolimus. The use of these antibodies may be effective to limit 
CNI exposure, but longer-term follow-up data are required (Flechner et al., 2008). Actually a 
recent study showed that induction with basiliximab resulted in 30-day and 1-year patient, 
graft and renal outcomes comparable with a control group receiving standard CNI-based 
immunosuppression. The authors concluded that antibody induction with delayed CNI 
should be further studied prospectively (Verna et al., 2011).Also a recent study showed that 
steroid-free alemtuzumab induction regimen was associated with less hypertension and 
rejection but with more infectious complications. Thus, the overall benefit of alemtuzumab 
induction in LT recipients is called into question (Levitsky et al., 2011). 
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CNI avoidance 
The use of the so-called renal-sparing agents is still debatable. Avoidance is hampered by 
lack of experience and possible sirolimus-induced side effects (delay in surgical wound 
repair because it inhibits fibrogenesis (Montalbano et al., 2004), inducing proteinuria, 
anaemia, thrombocytopenia, peripheral swelling, hypercholesterolemia and gastrointestinal 
disorders (Vivarelli et al., 2006). Use of sirolimus with mycophenolate mofetil to avoid CNI 
exposure de novo has improved glomerular filtration rate for at least two years in most 
studies in kidney transplantation; however, experience is limited in liver and heart 
transplantation, and reports of delayed graft function and wound healing with sirolimus 
may have dampened enthusiasm for de novo use. There is hardly published evidence for 
CNI-free de novo approaches with mTOR-inhibitors in liver transplant collectives. 
Schnitzbauer et al are conducting a prospective, noncontrolled, two-stage study 
(PATRON07) on patients with serum creatinine >1.5mg/dl or eGFR < 50 ml/min at the time 
of transplantation. Its objective is to evaluate the feasibility of a de novo CNI-free 
immunosuppressive regimen based on induction therapy with basiliximab (20 mg IV day 0 
and day 4 after transplantation), prednisolone 500mg during reperfusion then 1mg/kg and 
tapered by month 6 after LT, mycophenolate mofetil (2g/d bid), and mTOR-inhibition with 
sirolimus after day 10 after LT aiming at trough-levels of 4 to 10 ng/ml. The primary 
endpoint is defined as the incidence of steroid-resistant acute rejection within the first 30 
days after liver transplantation. The authors hope that the results of PATRON07 may be the 
basis for a large multicenter randomized controlled trial in patients with poor renal function 
at the time-point of liver transplant (Schnitzbauer et al., 2010). 
If CNI-free-"bottom-up” immunosuppression strategies are safe and effective, this may be 
an innovative concept that could improve the patient short and long-time outcome with 
regards to renal function, infectious complications and avoidance of over-
immunosuppression after LT. 
Future direction of immunosuppression: Costimulation blockade (Belatacept) 
Belatacept is a soluble cytotoxic T-lymphocyte antigen-4 (CTLA-4) agent which binds CD80 
and CD86 and inhibits T cell activation. Belatacept competes with the CD28 receptor on T 
cells which normally binds CD80 and CD86 on the antigen presenting cell as a co-
stimulatory signal required for T cell activation. Belatacept is administered intravenously 
once a month and does not carry the renal toxicity of CNIs. Clinical trials in liver transplant 
patients are currently ongoing with this agent (Pillai & Levitsky, 2009). 
3.5.3 Surgical technique of ‘piggy back’ 
It is necessary to conduct further studies in order to answer the question whether the new 
surgical technique of ‘piggy back’ type will allow for a reduction of AKI incidence 
(Cabezuelo et al., 2003 and 2006). 
3.6 Dialysis in the liver transplant patient 
Around 8-17% of the patients with AKI after LT require renal replacement therapy 
(Lewandowska  & Matuszkiewicz-Rowinska, 2011). Dialytic therapy in the immediate 
postoperative period requires close attention to hemodynamics and coagulation parameters. 
www.intechopen.com
 
Renal Dysfunction and Liver Transplantation 
 
289 
(Smith, 2006 and Lewandowska & Matuszkiewicz-Rowinska, 2011).The most frequently 
used perioperative treatment methods include continuous techniques in 75% of cases, such 
as continuous veno-venous haemo(dia)filtration (CVVHD), dialysis of SLED type (slow low 
efficiency dialysis), and intermittent haemodialysis in 25% of cases. Continuous techniques 
are preferred for two main reasons: the patients are frequently haemodynamically unstable 
and remain at a significant risk of brain oedema. However, the real advantage of these 
methods over the applied standard haemodialysis has not been proven so far. 
In the liver transplant patient with impaired hepatic clearance and renal failure, attention 
should be paid to the route of excretion of all pharmacologic agents given and doses 
adjusted accordingly. Cyclosporine, tacrolimus, prednisone, and mycophenolate mofetil are 
not removed by hemodialysis to any significant extent, while methylprednisolone and 
azathioprine (and its active metabolite mercaptopurine) are cleared partially during dialysis. 
Most angiotensin-converting enzyme inhibitors are dialyzable, with benazepril and 
quinapril being exceptions. Calcium channel blockers are generally not cleared by 
hemodialysis, while many of the beta-blockers (atenolol, acebutalol, metoprolol, nadalol, 
sotalol) are cleared. Because atenolol is primarily cleared by the kidneys, the dose to achieve 
a desired effect is much lower in patients with poor renal function. Metoprolol on the other 
hand is primarily metabolized by the liver. Metabolites of verapamil with atrioventricular 
(AV) node-blocking properties, but little antihypertensive effect can accumulate in patients 
on hemodialysis. This agent is thus best avoided in end-stage renal disease (Smith, 2006). 
In some of the cases, there may appear a need for renal replacement therapy during LT 
procedure mostly due to hypervolemia and the risk of brain oedema (Lewandowska & 
Matuszkiewicz-Rowinska, 2011). Townsend et al. used intraoperative CVVHD in 41 out of 
636 patients (6.4%) that they operated on. A mean time of dialysis was 258 minutes and a 
mean filtration rate was 1–1.5 l/h. No significant complications were observed apart from 
blood clotting in the dialyser (no anticoagulation was used in most of the patients) in 40% of 
cases. Indications included either typical, life threatening symptoms of AKI, such as 
overhydration or hyperkalemia, or disorders typical for this group of patients: lactic 
acidosis, hyponatremia, risk of brain oedema or necessity of transfusion of large volumes of 
blood preparations. In 78% of cases, CVVHD procedures were continued after OLT for 3–11 
days (Townsend et al., 2009). 
3.7 Prognosis of acute kidney injury 
Acute renal failure (ARF) has been associated with an 8-fold increase in mortality risk, 
prolonged ventilation time and intensive care unit (ICU) stay, greater risk for infectious 
complications, and greater hospital costs. De Simone et al reported an in-hospital mortality 
rate as high as 41% for patients with ARF versus 5% for those with preserved renal function 
(De Simone et al., 2009). Mortality of patients who required renal replacement therapy is 
from 45.1% to 67% (Cabezuelo et al., 2002, Faenza et al., 2006). 
Zhu and colleagues analysed retrospectively the influence of the renal function following LT 
on late clinical outcomes in 193 patients. Among patients with acute kidney injury (AKI), the 
28-day and 1-year mortality was significantly higher than in non-AKI patients (15.5% and 
25.9% vs. 0% and 3.9%, respectively; P<0.5). One-year survival of non-AKI patients was 96%, 
and of AKI patients in stage 1, 2, and 3– 85.5%, 84%, and 45.3%, respectively. The Cox 
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regression analysis showed that the independent risk factors of death in the first year 
following the transplantation included postoperative AKI (HR 12.1; P<0.05), postoperative 
infection (HR 4.7; P<0.01), postoperative hypertension (HR 4.4; P<0.01), and postoperative 
APACHE II index of ≥10 (HR 3.6; P<0.05) (Zhu et al., 2010). Similar results were published 
by Gonwa et al. (2001a) and by Ishitani et al. (1993). 
During the later course, renal dysfunction exerts an important influence on the quality of life 
of transplant recipients (Alessandria et al., 2005, Lewandowska & Matuszkiewicz-Rowinska, 
2011). AKI significantly increases the risk of development of chronic renal failure in the late 
post-LT period. The risk of developing chronic renal failure after LT is approximately 20% 
after 5 years, associated with the use of calcineurin inhibitors and a 4-fold increased 
mortality risk (Sharma et al., 2009 and Schnitzbauer et al., 2010). 
4. Chronic renal dysfunction 
With improved survival of liver transplant recipients, chronic kidney disease has emerged 
as a major long-term complication after OLT (Bahirwani & Reddy, 2009). In fact, liver 
transplant recipients have the highest five-yr incidence of CRF of any non-renal solid organ 
transplant recipient; additionally, the risk of death is at least fourfold higher in patients who 
develop CRF (Ojo et al., 2003). Numerous studies have been performed in the last decade in 
order to clarify the epidemiology and clinical significance of chronic kidney dysfunction 
among liver recipients (Fisher et al., 1998, Brown et al., 2001, Cohen et al., 2002 & Herlenius 
et al., 2008). 
4.1 Epidemiology of chronic renal dysfunction 
The incidence of chronic kidney disease (CKD) post-Liver transplant varies widely, from 10 
to 83%, most likely owing to the lack of a standard definition of post-transplantation chronic 
renal disease, differences in the methodology utilised to estimate renal function, and variable 
periods of follow-up (Fabrizi et al., 2010).The frequency of CKD (defined as eGFR <60 ml/min) 
according to recent series is listed in Table 5. However the incidence of the milder forms of 
renal dysfunction (GFR between ≥30 mL/min and ≤70 mL/min) is likely to be considerably 
higher than estimated (Fisher et al., 1998, Randhawa and Shapiro, 2005). Definitely, the 
incidence of CKD increases with time. The latest report on the epidemiology of CKD after 
liver transplantation has been offered by Lee et al (2010). A cohort of 431 recipients who 
underwent liver transplantation between 1997 and 2008 was included. The cumulative 
incidence of CKD (eGFR <60 ml/min) was 17% at 1 year, 23% at 3 years, and 27% at 5 years. 
Sharma et al., 2009 reported the cumulative incidence of post-LT CRF at 1, 3, and 5 years 
was 8%, 17% and 22%, respectively.  
Authors Frequency Time post-LT 
Lee J, et al (2010) 
Burra P, et al (2009) 
Kim S, et al (2004) 
De Boccardo G, et al (2008) 
17.6% (76/431) 
35.3% (143/406) 
43.5% (27/62) 
62.3% (144/231) 
12 months 
12 months 
17 months 
73 months 
Table 5. Epidemiology of chronic kidney disease among liver transplant recipients (CKD = 
eGFR <60 ml/min) 
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4.2 Definitions of chronic kidney disease 
The most common definition used is eGFR<60ml/min. Other definitions of CKD have been 
used. Gonwa and colleagues, defined post-LT CRD as sustained serum creatinine >2.5 
mg/dl. They reported that the combined incidence of CKD with end-stage renal disease (on 
RRT), was 4.3% at 5 years and 18% after 13 years of follow-up (Gonwa et al., 2001b). Ojo et 
al, 2003 in a larger study analyzed the data from the Scientific Registry of Transplant 
Recipients for 36,849 adult patients who had LT in the United States between 1990, and 2000. 
The incidence of post-LT CRD was 18% at 5 years and 26% at 10 years. This study defined 
post-LT CRD as GFR < 29 mL/minute/1.73 m2 or the development of end-stage renal 
disease, which was defined as initiation of RRT or listing for renal transplantation. 
Chronic renal dysfunction, not only has implications in terms of an increased demand on 
resources, but is also significantly associated with a higher patient mortality rate. Hence 
identification of the risk factors for its development of chronic renal dysfunction after liver 
transplantation is crucial. 
4.3 Risk factors for posttransplant chronic kidney disease 
Although previously attributed largely to calcineurin inhibitor toxicity (Ojo et al., 2003, 
Pillebout et al., 2005), it has become clear that the onset of chronic renal failure following LT 
is multifactorial, and reported to be correlated with posttransplant acute renal failure (Lee et 
al., 2010 and Tinti et al., 2010), pre-transplant renal dysfunction (Kamath et al., 2001; Burra et 
al., 2009 and Tinti et al., 2011), hepatitis C status, age, female gender, diabetes mellitus, 
hypertension, Model for End Stage Liver Disease (MELD), pretransplant proteinuria (Lee et 
al., 2010), pretransplant hepatorenal syndrome, alcohol intake (Hetz et al., 2005, Pillebout et 
al., 2005 and Randhawa & Shapiro, 2005), smoking and dyslipidemia (Sezer et al.,2011). 
4.3.1 Postoperative acute renal failure (ARF) and dialysis requirement in the post-
transplantation period 
Post-LT ARF was proved to be an early predictor of chronic kidney disease (CKD) in several 
studies (Ojo et al., 2003; Kim et al., 2004; Burra et al., 2009 and Sharma et al, 2009). Barri and 
his colleagues, 2009 stated clearly that the high incidence of acute kidney injury post–liver 
transplantation is an important risk factor for long-term renal dysfunction and its associated 
morbidity and mortality. Ojo et al., 2003 reported a relative risk of 2.13. In the study by Tinti 
and colleagues, post-LT CKD was present in 44.4% of patients with ARF in contrast to 6.7% 
of patients without ARF (Tinti et al., 2010). A multivariate Cox regression analysis revealed 
that the overall risk of CKD development (eGFR < 60 mL/min/1.73 m2) was associated with 
the existence of posttransplant ARF and its severity. In fact, a recent consensus conference 
on acute kidney injury(AKI) suggested that since AKI is a very strong predictor of CKD, a 
milder definition for AKI should be used to detect this problem early and to intervene 
before it is severe and progresses to CRD (Barri et al., 2009). 
4.3.2 Abnormal GFR at different intervals posttransplant 
Sanchez et al., 2010 in a study conducted on 592 liver transplant recipients also confirmed 
this finding and showed that patients with GFR less than 60 ml/min per 1.73 m2 at month 3 
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post-transplant have a higher risk of developing renal failure; however, those who avoid 
renal failure seem to maintain renal function long-term. Kamar et al. reported the eGFR after 
6 months was the only risk factor of renal failure for further 60±48 months. This was also a 
predictor of glomerular sclerosis found in 50% of glomerules in the renal biopsy performed 
afterwards (Kamar et al., 2011). Other studies have reported that an abnormal GFR at 1 year 
identifies patients at risk of chronic renal dysfunction (Cohen et al., 2002 & O’Riordan et al., 
2006).  
4.3.3 Pretransplant renal dysfunction 
Impaired pre-transplantat kidney function is a prognostic indicator for chronic kidney 
disease (CKD) following liver transplantation, as recently highlighted by a meta-analysis of 
clinical, observational studies. A stratified analysis including only studies provided with 
baseline GFR, revealed that the summary estimate of RR and 95% CIs for occurrence of 
chronic renal failure after liver transplantation in patients with diminished renal function at 
transplantation was 2.12 (95% CI, 1.01-4.46, p=0.01) (Fabrizi et al., 2011). Even relatively 
mild elevations in pre-transplant creatinine >1.5 mg/dL may portend poor long term renal 
function. This was confirmed by many investigators (Moreno et al., 2003, Kim et al., 2004 
and Burra et al., 2009). A multivariate Cox regression analysis performed by Lee et al 
revealed that the overall risk of CKD development was associated with low pre transplant 
eGFR in addition to post-transplant acute renal failure (Lee et al., 2010). In fact, Sharma et 
al., 2009 concluded that the estimated GFR at LT was the most important determinant of 
post-LT chronic renal failure. Sezer reported that after 5 years, GFR negatively correlated 
with initial Renal Resistive Index (r=-0.32; P<.01).  
Duration of pretransplant dysfunction 
Campbell (2005) suggested that duration, rather than the cause, of pretransplant renal 
dysfunction (pre-LT RD) is the key to predicting creatinine at 12 months after 
transplantation. ROC analysis among LT alone patients showed that the duration of renal 
disease by itself had a moderate ability to predict creatinine >1.5 mg/dL at 12 months 
posttransplantation (area under ROC curve = 0.71). The optimal predictive cutoff was 3.6 
weeks. However they stated that they cannot at this time recommend that all patients with 
duration of renal disease longer than 3.6 weeks undergo combined liver kidney 
transplantation (CLKT) since creatinine of 1.5 mg/dL 1 year after transplantation is not 
necessarily high enough to justify concomitant renal transplantation. Instead they 
recommended that a threshold duration of renal dysfunction in combination with other 
predictive clinical variables (e.g height of creatinine, requirement for RRT) be prospectively 
investigated as an aid to clinical decision making. 
Indeed for liver transplant (LT) candidates with pretransplant mild to moderate chronic 
renal impairment or recent-onset ARF, the decision of whether to perform LT alone or CLKT 
can be challenging because no single factor has been shown to be predictive of the degree of 
progression of chronic kidney disease following successful LT. Although Pham et al., 2007 
suggested, like Campbell, that the duration of pretransplant renal dysfunction had a 
negative impact on posttransplant renal function outcome, Marik et al., 2006 and Sharma et 
al., 2009, in contrast, failed to demonstrate that the duration of pretransplant renal 
dysfunction was predictive of post-LT renal outcome. 
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4.3.4 Calcineurin inhibitors (CNI) 
Chronic CNI nephrotoxicity is caused by immunological and non-immunological damage. 
Histopathological examination shows renal tubular atrophy with typical microcalcification, 
patchy fibrosis and nodular arteriolar hyalinosis. According to Mihatsch, arteriolopathy, the 
main symptom of CNI nephrotoxicity, is a variant of thrombotic microangiopathy with 
slow, subclinical course. Differentiation between arteriolar hyalinosis associated with CNI 
administration and arteriolar sclerosis in hypertension, diabetes, or the elderly poses a 
challenge. A typical feature of CNI toxicity is substitution of smooth muscle cells by hyaline 
deposits in the external media layer; while in arteriolar hyalinosis in other clinical situations 
the smooth muscle cells are intact and hyaline deposits accumulate beneath the endothelium 
(Mihatsh et al., 1994).  
There is no precise classification to assess CNI nephrotoxicity; that is why new scales and 
classifications are developed in order to enhance the precision of diagnosing CNI 
nephrotoxicity. The new scales to evaluate CNI nephrotoxicity, like the older ones, show 
arteriolar hyalinosis as the most typical abnormality (Kambham et al., 2007). One histologic 
study reported the association of these changes with cyclosporine dose and over time. Mild 
arteriolar hyalinosis at six months appeared to be associated with high doses and was 
reversible. By comparison, at three years, irreversible severe arteriolar hyalinosis and 
glomerosclerosis was observed, despite decreased doses and trough levels (Nankivell et al., 
2003). 
 
Fig. 3. Nodular hyalinosis typical of CNI (John et al., 2010) 
Chronic lesions and acute nephrotoxicity in CNI treatment are caused by various mediators, 
including renin–angiotensin–aldosterone (RAA) system, which by activating angiotensin 
type 1 receptor is not only a contributory factor in renal vascular bed constriction, but also 
influences kidney fibrosis and aldosterone release. Activation of RAA system through CNI 
may cause harmful hemodynamic (vasoconstriction) and nonhemodynamic changes (via 
enhanced synthesis of transforming growth factor-β, vascular endothelial growth factor and 
enhanced renal cell apoptosis) (Friedlander, 2007). The CNI-induced TGF-β formation 
produces tubulointerstitial fibrosis by increased synthesis and decreased extracellular 
matrix degradation (Khanna et al., 2002). Administration of losartan, AT1 blocker, in 
transplant patients leads to a significant decrease in TGF-β serum levels and increased GFR 
(Campistol et al., 2001). 
Recent trials have shown that aldosterone, the final product in the RAA system, may play an 
important role in CNI nephrotoxicity; therefore, spironolactone administration may be an 
effective strategy in the prevention of CNI nephrotoxicity (Perez-Rojas et al., 2007). During 
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CNI treatment, disturbances in nitric oxide (NO) release and NO synthase activity may 
generate reactive oxygen species; all of them might be involved in tubular epithelial to 
mesenchymal transition (Sharma et al., 2000 and Han et al., 2006). Protein kinase C (PKC-β) 
contributes to CNI-dependent fibrosis. It has been proved that cyclosporine administration 
enhanced PKC-β mRNA and protein expression; adding hispidine, a PKC-β inhibitor, 
inhibited TGF-β1 synthesis in proximal tubule cells (Liu, 2006).Genetic susceptibility to 
cyclosporine nephrotoxicity has been suggested. Cyclosporine is a substrate for the 
transmembrane pump P-glycoprotein. There is some evidence in animals and in vitro that 
decreased expression of this pump may contribute to increased cyclosporine levels, leading 
to nephrotoxicity. Altered protein pump expression has also been observed in association 
with several polymorphisms in its gene. As an example, the TT genotype is associated with 
decreased P-glycoprotein expression in the kidney. In a case control study of donor and 
recipient pairs, the TT genotype in the donor directly correlated with chronic cyclosporine 
nephrotoxicity in the allograft recipient. This suggests that underlying genetic factors that 
increase cyclosporine concentrations in the kidney may contribute to chronic nephrotoxicity 
(Hauser et al., 2005). 
Progressive obliterative arteriolopathy and chronic interstitial fibrosis with glomerulosclerosis 
develop in LT recipients in a dose-dependent and time-dependent fashion and have limited 
potential for reversibility (Fabrizi et al., 2010).  
Manifestations of Chronic calcineurin inhibitor nephrotoxicity: renal insufficiency due to 
glomerular and vascular disease, abnormalities in tubular function, and an increase in blood 
pressure (Hauser et al., 2005).  
Abnormalities in tubular function include:  
- hyperkalemia (due to reducing of potassium excretion both by decreasing the activity of 
the renin-angiotensin-aldosterone system and by impairing tubular responsiveness to 
aldosterone) (Tumlin and Sands, 1993).  
- hypophosphatemia (due to urinary phosphate wasting) (Moz et al., 2004) 
- hypercalciuria (Nijenhuis et al., 2004). 
- hypomagnesemia — presumably due to drug effects on magnesium reabsorption. 
Hypomagnesemia has been implicated as a contributor to the nephrotoxicity associated 
with cyclosporine (Miura et al., 2002).  
Difference between cyclosporine and tacrolimus: There are conflicting views in the literature 
regarding any difference in the nephrotoxic effect of either cyclosporine or tacrolimus. Many 
investigators did not identify any difference in the impact of either drug on the immediate 
postoperative kidney function (Burra et al., 2009, Dehghani et al., 2008, Kim et al., 2004 and 
Wei et al., 2006). On the other hand, O’Riordan et al., 2006 found a beneficial effect of 
tacrolimus use, compared with cyclosporine, which retarded the progression of acute renal 
disease to chronic renal disease. This has been previously noted by Filler et al., 2005 and 
Lucey et al., 2005. In contrast, a previous long-term trial comparing cyclosporine and 
tacrolimus in liver transplant recipients found a similar incidence of early acute renal failure 
and late hypertension, while late renal insufficiency was more prevalent with tacrolimus 
(Porayko et al., 1994). Recently, Lee and colleagues, 2010 in a multivariate Cox regression 
analysis revealed that the overall risk of CKD development was associated with 
cyclosporine more than tacrolimus.  
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4.3.5 Hepatitis C  
Hepatitis C recurrence after transplant is almost universal. Infection with hepatitis C virus 
(HCV) is the leading indication for LT worldwide and one explanation for the higher 
incidence of renal failure in LT patients is that HCV per se and the severity of HCV 
recurrence are risk factors for renal dysfunction (Asfandiyar et al., 2006). The mechanism by 
which HCV infection may induce early renal failure is not yet fully understood. HCV 
infection has been associated with mesangiocapillary glomerulonephritis and 
cryoglobulinemia (Braun et al., 2003), conditions that have been reported in HCV+ve LT 
recipients (Abrahamian et al., 2000 and Kendrick et al., 1997). Immunosuppressive therapy 
results in an early and significant increase in HCV replication after LT (Gane et al.., 1996), 
which may increase the risk of glomerular damage if concurrent renal transplantation is not 
performed [Pascual et al., 1997]. Moreover in these series, the presence of lower GFR before 
transplant (although not statistically significant) and the significant higher incidence of 
diabetes mellitus after transplantation in HCV group, compared to non-HCV group, could 
be additional factors justifying the worse renal function of HCV+ve liver transplant 
recipients (Burra et al., 2009). 
Studies have reported a different influence of hepatitis C on chronic renal dysfunction after 
liver transplantation. Pillebout (2005) found a strong association linking HCV infection with 
end-stage renal disease at biopsy, relating particularly to interferon therapy. In contrast, 
Burra et al., 2009 found no such association between the onset of chronic renal failure and 
the use of interferon before or after LT. Instead they stressed that HCV status had a negative 
impact on the median GFR in the first year of liver transplantation. Later on, HCV may lose 
this negative impact, while early stage renal failure continues to play a part in impaired 
renal function. Actually this study stated that HCV status, pre-LT GFR and serum creatinine 
levels were independent predictors of renal function a year after LT. Asfandiyar and 
colleagues, 2006 also demonstrated that infection with hepatitis C is an independent risk 
factor for chronic kidney disease as well as the relation with severity of HCV. Actually, Ojo 
et al., 2003, found that HCV was an independent risk factor for chronic renal dysfunction 
after all non-renal solid organ transplants and not just liver transplantation. 
4.3.6 Glomerulonephritis 
Only a few, small-sized studies on the histological features of chronic kidney disease (CKD) 
among LT recipients exist. In addition to histological lesions attributable to calcineurin 
inhibitor toxicity, a large spectrum of glomerular abnormalities was noted. Gonwa et al 
observed calcineurin inhibitor toxicity (n=33; 73%), non-recovered HRS (n=3; 7%), and focal 
segmental glomerulosclerosis (n=3; 7%) in their cohort of 45 patients who underwent kidney 
biopsy post-liver transplantation (Gonwa et al., 2001b). In another study by Pillebout, chronic 
renal failure was attributed to (i) specific chronic cyclosporine/tacrolimus arteriolopathy; 
(ii) typical diabetic nephropathy; (iii) acute or chronic thrombotic microangiopathy 
attributed to cyclosporine/tacrolimus arteriolopathy or alpha-interferon (Pillebout et al., 
2005). In hepatitis B, CNI toxicity and focal segmental sclerosis, but not immune-complex 
disease, were revealed as significant contributors to CKD after LT (Lee et al., 2010). The 
question whether those cases with glomerular lesions represent de novo glomerulonephritis 
or progression of pre-existing disease was unanswered; only prospective studies with serial 
kidney biopsies can address this point (Fabrizi et al., 2010). Pre-transplant proteinuria is a 
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significant and independent risk factor for CKD after liver transplantation, according to Lee 
et al., 2007 and O’Riordan et al., 2006.  
4.3.7 Pre-existing comorbidities such as diabetes mellitus, hypertension 
A few studies have looked at the relation between diabetes mellitus and hypertension and 
chronic renal dysfunction. Karie-Guigues et al., 2009 reported incidence rates of 10.5% for 
pre-LT hypertension and 43.4% for new-onset hypertension at one year post-
transplantation. Diabetes mellitus was reported in 12.5% of the patients before LT and 19.2% 
developed new onset diabetes after one year of LT. They showed that neither hypertension 
nor diabetes (pre-transplant or de novo for both) were significantly associated with a GFR 
decrease at any time points after LTx. These results are in line with those previously 
reported by Ojo et al, 2003 for hypertension and by O’Riordan et al, 2006 for diabetes. 
4.3.8 Child-pugh score and high model for end-stage renal disease (MELD) score 
At 3 years after LT, GFR negatively correlated with initial Child-Pugh score (Sezer et al., 
2011) and pretransplantat direct bilirubin. After 5 years, GFR negatively correlated with 
prothrombin time (r=-0.29; P<.05). Overall risk of CKD development (eGFR < 60 
mL/min/1.73 m2) was associated with high Child-Pugh score and high Model for End-Stage 
Renal Disease (MELD) score (Lee et al., 2010). Especially in recipients whose pre-operative 
eGFR was high (>or=60 mL/min/1.73 m2), rapid progression of kidney disease was 
associated with Child-Pugh score (in addition to high tacrolimus level and posttransplant 
acute renal failure) (Fabrizi et al., 2011).  
4.4 Prevention of CKD 
Especially patients undergoing LT for HCV may benefit particularly from methods for 
protecting kidney function, such as: 
- an optimal control of glucose metabolism,  
- dyslipidemia and proteinuria, and an  
- aggressive blood pressure containment treatment (Opelz et al., 1998, Randhawa and 
Shapiro, 2005 and Pillebout et al., 2005). 
- Minimizing CNI exposure. Use of CNIs is an important contributor to CRF after liver 
transplant, accounting for >73% of the renal diagnoses in those patients, (Gonwa et al., 
2001b) and this had led to a number of strategies to minimize CNI exposure (mentioned 
above). 
4.5 Outcome of chronic kidney disease after liver transplantation 
4.5.1 CVS morbidity/mortality 
Chronic kidney disease is a known risk factor for cardiovascular morbidity/mortality in the 
non-transplantation setting. The Heart Outcomes and Prevention Evaluation (HOPE) study 
suggested that even mild renal insufficiency was a significant risk factor for a subsequent 
cardiovascular event (Mann et al., 2001). The Cooperative Cardiovascular project 
demonstrated that the mortality risk for patients with moderate renal insufficiency for 
myocardial infarction was three times higher than that of patients with intact kidney 
function (Shlipak et al., 2002). These results suggest that renal insufficiency is an 
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independent risk factor for cardiovascular disease and should be considered in addition to 
other traditional risk factors. Transplant recipients are at increased risk of cardiovascular 
disease, and information gained in the last decade suggests that the occurrence of CKD 
appears to further increase the burden of cardiovascular disease among LT recipients. 
Therefore, the most common endpoint among LT recipients with CKD is not the need for 
renal replacement therapy or kidney transplantation but death secondary to cardiovascular 
disease (Fabrizi et al., 2010). 
Calcineurin inhibitors also contribute to the development of diabetes mellitus, dyslipidemia, 
hypertension, and oxidative stress, all of which contribute to cardiovascular morbidity 
(Merville, 2005). 
4.5.2 Mortality 
The occurrence of CKD after liver transplantation has a major impact on post-LT mortality. 
Many investigators confirmed this observation. Moreno et al evaluated 289 consecutive LT 
patients with post-transplant follow-up longer than 6 months. Patient survival was 
significantly lower among LT patients with chronic renal dysfunction than in those without 
this complication (63% vs. 71%, p=0.024). Ojo (2003) conducted a population-based cohort 
analysis among 69,321 persons who received non-renal transplants (liver, lung, heart, 
intestine, heart-lung) in the United States between 1990 and 2000. The occurrence of CRF 
significantly increased the risk of death (RR, 4.55; 95% CIs, 4.38 to 4.74; P<0.0001). The 13-
year survival rate in patients with end-stage renal disease posttransplant in a study 
performed by Gonwa et al., 2001 was only 28.2% versus 54.6% in those without 
posttransplant kidney disease. 
Sharma (2009) evaluated retrospectively 221 adult LT recipients who had LT in the MELD 
era (Feb 2002-Feb 2007). In their multivariate analysis, the decrease in GFR during post-LT 
follow-up was the only independent predictor of post-LT mortality after adjustment for age, 
etiology, MELD score, and GFR at liver transplantation. The risk of post-LT patient 
mortality was 2.9 (1.3-6.4; p=0.008) for patients with GFR <30 versus >30-60 ml/min and 3.2 
(1.19-8.67; p=0.02) for patients with GFR <30 versus>60 ml/min. Pawarode (2003) studied 
172 consecutive LT recipients over a median follow-up of 72.4 months (range, 6.5 to 100.6 
months). Severe renal failure was associated with significantly lower survival by Cox 
regression analysis (p=0.004). O’Riordan (2006) followed 230 patients after liver 
transplantation over 5.6 years (Irish National Liver Transplant database); the 10-year 
cumulative incidence of CKD stage 4 (GFR 15-29 ml/min) and 5 (dialysis or GFR <15 
ml/min) was 6.1% and 2.6%, respectively. Cox regression analysis of overall patient survival 
suggested that the post-LT GFR < 30 ml/min was associated with a hazard ratio of 3.05 (95% 
CI, 1.21-7.7; p=0.02); the other independent risk factors of lower patient survival being 
fulminant hepatic failure and retransplantation. 
Authors Relative Risk P 
Ojo A, et al (2003) 4.55(4.38;4.74) 0.001 
Pawarode A, et al (2003) NA 0.004 
O’Riordan A, et al (2006) 3.05 (1.21;7.70) 0.02 
Sharma P, et al (2009) 3.2 (1.19;8.67) 0.02 
Table 6. Impact of Posttransplant Chronic renal dysfunction on Mortality 
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5. Conclusions 
• There has been abundant evidence over the last decade on the importance of kidney 
dysfunction among liver transplant recipients. However, still questions need to be 
assessed. 
• Acute kidney injury (AKI) has significant prognostic implications for long-term 
outcomes in patients undergoing liver transplantation. Hence, every effort has to be 
undertaken to preserve renal function throughout all stages of patient care. 
• In this review we discussed the important risk factors that negatively affect kidney 
function. A specially increased risk frequently exists among liver transplant recipients 
with pretransplant renal dysfunction. 
• Diagnosis of acute kidney injury was also discussed. To better define acute kidney injury, 
new markers (e.g. neutrophil gelatinase-associated lipocalin) have become available 
that help to identify patients at risk for renal injury within hours of a triggering insult. 
Larger studies are required to validate the results. These newly established markers for 
injury, such as NGAL, in conjunction with improved markers for renal function will 
allow us to further delineate the natural course of AKI during liver transplantation. 
• The occurrence of chronic kidney disease after liver transplantation has a major impact on 
mortality. Additional studies are needed to understand better the natural history of 
chronic kidney disease among liver transplant recipients. Strategies need to be put in 
place for the early detection of these individuals and then preventive measures 
introduced to retard the progression of chronic kidney disease.  
• Hepatitis C appears to be an additional risk factor affecting renal function in the long 
term in liver transplanted patients. Further dedicated prospective studies aiming to 
evaluate the possible pathogenetic mechanism of HCV damage on long-term renal 
function after liver transplantation are needed. For the present time, it would be 
advisable to avoid combinations of risk factors for renal impairment, at least in the first 
year after LT in HCV+ve recipients. 
• Modification of nephrotoxic immunosuppressive regimens to avoid postoperative acute 
renal failure and/or chronic renal failure has met with variable results. Although there 
is no well-defined protocol to prevent or minimize cyclosporine or tacrolimus 
nephrotoxicity, some centers currently advocate the use of a calcineurin-sparing 
protocol adjusted for the degree of renal dysfunction. Hence, the clinical evaluation of 
the presence of multiple risk factors for renal insufficiency and etiology of liver disease 
would be important to select patients who would benefit from a renal sparing regime of 
immunosuppression. However, dedicated large studies meticulously evaluating these 
renal sparing regimes in patients with risk factors for renal dysfunction are still 
recommended. Also trials on novel agents targeting different sites of the immune 
cascade and without renal toxicity are on the way. Until then, finding the balance 
between preserving graft function and optimizing immunosuppression while 
minimizing renal toxicity remains a challenge. 
• Studies that incorporate renal diagnosis and other prognostic indicators (such as 
proteinuria) to stratify liver transplant candidates according to risk for kidney 
dysfunction post-liver transplant are in progress.  
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